Journey Medical Corporation announced that the FDA has accepted the Company's New Drug Application (NDA) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of November 4, 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.605 USD | +0.98% | -1.38% | -37.85% |
05-01 | Journey Medical Corporation Appoints Joseph M. Benesch as Chief Financial Officer | CI |
03-21 | Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.85% | 71.3M | |
+33.20% | 698B | |
+26.51% | 568B | |
-4.43% | 358B | |
+19.24% | 328B | |
+3.89% | 283B | |
+16.42% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+7.83% | 165B |
- Stock Market
- Equities
- DERM Stock
- News Journey Medical Corporation
- Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea